BioCentury

Dual TLR7 and TLR8 agonism for pancreatic cancer

November 4, 2019 4:56 PM UTC

INDICATION: Pancreatic cancer

Agonizing stromal TLR7 and TLR8 could treat pancreatic ductal adenocarcinoma (PDAC). In mice with PDAC, a TLR7 and TLR8 agonist tool compound reduced tumor growth and hallmarks of cachexia, including decreased food intake, body weight and locomotor activity. Continuous daily treatment nearly doubled the duration of survival (28 days vs. 15 days for vehicle) in the mice, and the therapeutic effect depended on TLR7 expression in stromal tissues. ...